title: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
abstract: Anaplastic thyroid carcinoma (ATC) affects primarily elderly patients, with a median survival of 4-12 months after diagnosis. Presently, under clinical investigation the combination of cisplatin (CDDP) and gemcitabine (GEM) has promising activity in several of human tumor types. To develop new approaches for therapy of ATC, we evaluated the antineoplastic activity of GEM and CDDP alone (1-h and 24-h drug exposure) or in combination in the ATC cell lines SW1736, 8505C, C643, and HTh74. IC50 values were determined by the sulforhodamine B assay, activity was evaluated by the relative antitumor activity (RAA) and drug interaction assessed by isobologram analysis. GEM seemed to be active in ATC, with RAA ranging from 12-114 and CDDP only modestly active (RAA, 0.24-1.4). In four different drug schedules tested, the drug combination was additive when GEM preceded CDDP exposure (combination index, approximately 1), whereas when CDDP preceded GEM exposure the combination was significantly antagonistic (combination index, >1). In SW1736 and 8505C cells, we observed a strong S phase arrest and DNA synthesis inhibition 24 h after a 1-h exposure to an IC50 of CDDP. On the basis of molecular drug targets, cell cycle arrest points, and DNA synthesis inhibition, a model was developed to explain the interaction observed for the combination of GEM and CDDP. In conclusion, GEM shows promising cytostatic activity in ATC. Interaction of GEM and CDDP was schedule and dose dependent, favoring a regime in which GEM is followed by CDDP. Additionally, our model system suggests that DNA-synthesis inhibition and S phase arrest may be important determinants for the drug interaction between GEM and CDDP.
authors.affiliation: Klinik für Innere Med IV, Martin-Luther-Universität Halle, Halle/Saale, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Voigt
authors.forename: A
authors.initials: A
authors.lastname: Bulankin
authors.forename: T
authors.initials: T
authors.lastname: Müller
authors.forename: C
authors.initials: C
authors.lastname: Schoeber
authors.forename: A
authors.initials: A
authors.lastname: Grothey
authors.forename: C
authors.initials: C
authors.lastname: Hoang-Vu
authors.forename: H J
authors.initials: HJ
authors.lastname: Schmoll
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004357:Drug Synergism; D006801:Humans; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D004247:DNA; D002945:Cisplatin; D000093542:Gemcitabine